A Combined Biomarker of Peripheral PD-1+ T Cells and Tumor PD-L1 Guides First-Line Treatment Selection in NSCLC: A Prospective Cohort Study

Background Selecting first-line therapy for advanced non-small cell lung cancer (NSCLC) without driver mutations is challenging due to a lack of predictive biomarkers. Tumor PD-L1 testing is invasive, heterogeneous, and imperfect for identifying patients at risk of hyperprogression. We investigated non-invasive biomarkers to guide treatment choice between chemo-immunotherapy and chemo-antiangiogenic therapy. Methods This prospective cohort study enrolled 66 treatment-naïve patients with metastatic NSCLC. Patients received either first-line chemo-immunotherapy (n = 37) or chemo-antiangiogenic therapy (n = 29). We compared progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). The predictive value of tumor PD-L1 expression combined with PD-1 expression on peripheral blood CD4 + and CD8 + T cells was assessed. Results No significant differences were found between the two treatment groups in median PFS (7.9 vs. 9.2 months, P = 0.357), OS (20.8 vs. 19.8 months, P = 0.616), or ORR (32.4% vs. 41.4%, P = 0.623). However, within the chemo-immunotherapy group, patients with high PD-L1 and/or high PD-1 on CD4+/CD8 + T cells had significantly superior PFS (HR 0.18, P = 0.006) and OS. In the chemo-antiangiogenic group, low PD-1 on CD4 + T cells predicted better survival (mOS: 24.9 vs. 9.3 months, P = 0.032). Adverse events were comparable. Conclusion First-line chemo-immunotherapy and chemo-antiangiogenic therapy showed comparable efficacy in an unselected population. A composite biomarker of peripheral PD-1 + T cells and tumor PD-L1 effectively identified patients with superior survival benefits from immunotherapy, offering a promising non-invasive strategy for personalizing initial NSCLC treatment.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11457517/v1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

A Combined Biomarker of Peripheral PD-1+ T Cells and Tumor PD-L1 Guides First-Line Treatment Selection in NSCLC: A Prospective Cohort Study

Wenyun Jia, Zhe Qian, Qunhui Wang, Xiaomi Li et al.
Research Square
Cancer Immunotherapy and Biomarkers
preprint

A Combined Biomarker of Peripheral PD-1+ T Cells and Tumor PD-L1 Guides First-Line Treatment Selection in NSCLC: A Prospective Cohort Study

Wenyun Jia, Zhe Qian, Qunhui Wang, Xiaomi Li, tongmei zhang, baolan li
preprint en

Abstract

Background Selecting first-line therapy for advanced non-small cell lung cancer (NSCLC) without driver mutations is challenging due to a lack of predictive biomarkers. Tumor PD-L1 testing is invasive, heterogeneous, and imperfect for identifying patients at risk of hyperprogression. We investigated non-invasive biomarkers to guide treatment choice between chemo-immunotherapy and chemo-antiangiogenic therapy. Methods This prospective cohort study enrolled 66 treatment-naïve patients with metastatic NSCLC. Patients received either first-line chemo-immunotherapy (n = 37) or chemo-antiangiogenic therapy (n = 29). We compared progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). The predictive value of tumor PD-L1 expression combined with PD-1 expression on peripheral blood CD4 + and CD8 + T cells was assessed. Results No significant differences were found between the two treatment groups in median PFS (7.9 vs. 9.2 months, P = 0.357), OS (20.8 vs. 19.8 months, P = 0.616), or ORR (32.4% vs. 41.4%, P = 0.623). However, within the chemo-immunotherapy group, patients with high PD-L1 and/or high PD-1 on CD4+/CD8 + T cells had significantly superior PFS (HR 0.18, P = 0.006) and OS. In the chemo-antiangiogenic group, low PD-1 on CD4 + T cells predicted better survival (mOS: 24.9 vs. 9.3 months, P = 0.032). Adverse events were comparable. Conclusion First-line chemo-immunotherapy and chemo-antiangiogenic therapy showed comparable efficacy in an unselected population. A composite biomarker of peripheral PD-1 + T cells and tumor PD-L1 effectively identified patients with superior survival benefits from immunotherapy, offering a promising non-invasive strategy for personalizing initial NSCLC treatment.

Research Square
Capital Medical University (CN)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon